tiprankstipranks
Blurbs

Dawson James Sticks to Their Buy Rating for Cytosorbents (CTSO)

Dawson James analyst Jason Kolbert maintained a Buy rating on Cytosorbents (CTSOResearch Report) on November 9 and set a price target of $16.00. The company’s shares closed last Tuesday at $4.03.

According to TipRanks.com, Kolbert is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytosorbents with a $12.75 average price target, representing a 195.8% upside. In a report issued on November 5, Leerink Partners also maintained a Buy rating on the stock with a $15.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Cytosorbents’ market cap is currently $175.2M and has a P/E ratio of -10.96.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CTSO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Read More on CTSO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed